HBM Healthcare Investments Gains from Parabilis Medicines' Successful IPO

HBM Healthcare Investments has seen a positive impact from the successful initial public offering (IPO) of its portfolio company, Parabilis Medicines. Parabilis, a clinical-stage biopharmaceutical firm, focuses on innovative cancer therapies. The IPO was priced at USD 20.00 per share, issuing 33.5 million new shares. This resulted in gross proceeds of approximately USD 670 million, giving Parabilis a market capitalisation of about USD 2.6 billion.

Since 2021, HBM invested USD 13.6 million in Parabilis, with a reported carrying value of USD 11.3 million as of March 2026. Post-IPO, HBM maintains around a 1% stake in Parabilis. With the first trading day closing price at USD 31.60, this stake's value is estimated at USD 37.7 million. This marks the second successful IPO from HBM's portfolio this year, following Odyssey Therapeutics.